Retinal diseases affect millions of people worldwide – leading to irreversible sight loss and a dramatic decline in quality of life. Beacon Therapeutics is changing that.
The company is pioneering next-generation gene therapies to slow, stop, or even reverse degenerative eye diseases that until now have been considered incurable.
Co-founded in 2023 by Professor Robert MacLaren – Professor of Ophthalmology at The University of Oxford – Beacon Therapeutics is an Oxford spinout on a mission to preserve and enhance the vision of patients suffering from widespread and rare retinal diseases.
